Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBiomarker/Laboratory analysis, TreatmentClosed18 and overNCI, OtherRTOG 1014
CDR0000666991, NCT01082211

Trial Description


RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery kill any remaining tumor cells and may be an effective treatment for breast cancer.

PURPOSE: This phase II trial is studying how well radiation therapy works in treating women with locally recurrent breast cancer previously treated with repeat breast-conserving surgery.

Further Study Information



  • To evaluate skin, breast, and chest wall adverse events occurring within 1 year after completion of 3D-conformal partial-breast re-irradiation following repeat breast-preserving surgery in patients with locally recurrent breast carcinoma.


  • To evaluate the adverse events at 1 year and at any time of this regimen in these patients.
  • To evaluate in-breast control rate in patients treated with this regimen.
  • To evaluate freedom-from-mastectomy rate in these patients.
  • To evaluate the rate of circulating tumor cells (CTCs) in this patient population and to document eradication of CTCs by locoregional therapy.
  • To determine whether translational objective will correlate with eradication or presence of CTCs with in-breast recurrence and distant metastasis-free survival.
  • To evaluate cosmesis as judged by the patient and independent evaluation.
  • To evaluate distant metastasis-free survival, mastectomy-free survival, and overall survival of patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients undergo 3-dimensional conformal accelerated partial-breast irradiation twice daily, 5 days a week, for 3 weeks.

Some patients undergo blood sample collection at baseline and within 3 weeks after completion of radiotherapy for circulating tumor cells analysis.

Some patients complete questionnaires on cosmesis at baseline and at 1 and 3 years following radiotherapy.

After completion of study therapy, patients are followed up periodically for 4-5 years and then every year thereafter.

Eligibility Criteria


  • Histologically confirmed locally recurrent breast carcinoma consistent with the following cell types:
  • Invasive ductal breast carcinoma
  • Medullary ductal breast carcinoma
  • Tubular ductal breast carcinoma
  • Mucinous ductal breast carcinoma
  • Lobular breast carcinoma
  • Ductal carcinoma in situ (DCIS)
  • No Paget disease of the nipple
  • Initial lumpectomy followed by whole-breast radiotherapy performed over 1 year ago
  • Repeat lumpectomy performed within the past 42 days
  • Target lumpectomy cavity must be clearly defined and the target lumpectomy cavity/ whole-breast reference volume must be < 30% based on a post-operative, pre-treatment CT scan
  • Histopathologic confirmation via lumpectomy of local in-breast ipsilateral recurrence within the past 120 days and the following must be true:
  • Tumor size ≤ 3 cm in greatest dimension on pathologic specimen
  • Negative histologic margins of resection and no tumor on ink following breast-preserving surgery
  • Re-excision to achieve negative margins allowed
  • Axilla negative or ≤ 3 positive lymph nodes without extracapsular extension
  • If the in-breast recurrence is DCIS and/or microinvasive disease, a sentinel lymph node (SLN) evaluation is not required, but if performed:
  • Patients with a negative sentinal lymph node (SLN) biopsy are eligible for enrollment
  • Patients with a positive SLN biopsy require an axillary lymph node (ALN) dissection (ALND is not required if the SLN is not identified)
  • Patient is eligible if 0-3 positive ALNs without extracapsular extension is documented
  • If the in-breast recurrence is invasive disease and:
  • No prior ALN dissection or SLN dissection only:
  • Patient is required to undergo axillary evaluation with either a SLN or ALN dissection
  • If the SLN is not identified or if the SLN is positive for metastatic disease then an ALN dissection is required
  • Patient is eligible for enrollment if encounter 0-3 positive lymph nodes without extracapsular extension
  • • Prior ALN dissection: negative clinical exam: patient is eligible for enrollment
  • It is recommended, but not required, that the patient undergo ultrasound evaluation of the axilla and the lymph node draining regions of the breast; any suspicious areas are to be biopsied and if positive followed with an ALN dissection
  • Patient is eligible for enrollment if biopsies are negative or 0-3 axillary lymph nodes without extracapsular extension are encountered
  • Prior ALN dissection: positive clinical exam: biopsy required
  • If biopsy is negative, patient is eligible for enrollment
  • If biopsy is positive an ALN dissection is required
  • Patient is eligible for enrollment if biopsies are negative or 0-3 axillary lymph nodes without extracapsular extension encountered
  • Ipsilateral breast mammogram and MRI within 120 days prior to study entry
  • Contralateral breast mammogram within 12 months of study entry
  • No more than 120 days since whole-body PET-CT scan OR CT scan of the chest, abdomen, and pelvis, and bone scan
  • No multicentric ipsilateral breast recurrence or regional recurrence (other than axilla)
  • Patients must have a breast technically amenable to partial-breast irradiation
  • No metastatic disease documented by physical exam or radiographic evaluation (for patients with invasive disease)
  • No skin involvement
  • No prior contralateral mastectomy
  • Estrogen and progesterone status must be known


  • Zubrod performance status 0-1
  • Menopausal status not specified
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other invasive malignancy within the past 3 years except ipsilateral breast cancer and/or nonmelanoma skin cancer
  • No collagenous diseases, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis
  • No psychiatric or addictive disorders that would preclude obtaining informed consent


  • See Disease Characteristics
  • More than 2 weeks since prior chemotherapy and recovered
  • No concurrent intensity-modulated radiotherapy
  • No concurrent chemotherapeutic agents, including trastuzumab

Trial Contact Information

Trial Lead Organizations/Sponsors

Radiation Therapy Oncology Group

  • National Cancer Institute
Douglas W. Arthur, Principal Investigator

Trial Sites


New Jersey
Long Branch

Monmouth Medical Center

Sang Eui Sim
Ph: 732-923-7689

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01082211
ClinicalTrials.gov processed this data on May 11, 2015

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.